- Home
- RMCF vs NRSN Comparison
RMCF vs NRSN Comparison
Compare RMCF & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RMCF | NRSN |
|---|---|---|
| Founded | 1981 | 2017 |
| Country | United States | Israel |
| Employees | N/A | 15 |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.2M | 28.4M |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | RMCF | NRSN |
|---|---|---|
| Price | $2.55 | $0.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 46.2K | ★ 132.7K |
| Earning Date | 04-24-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,432,352.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.12 | $0.68 |
| 52 Week High | $2.99 | $2.60 |
Technical Indicators
Market Signals| Indicator | RMCF | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 49.79 | 43.97 |
| Support Level | $2.36 | $0.68 |
| Resistance Level | $2.60 | $1.30 |
| Average True Range (ATR) | 0.15 | 0.06 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 25.32 | 29.71 |
Price Performance
Historical ComparisonAbout RMCF Rocky Mountain Chocolate Factory Inc.
Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, U-Swirl Operations, and Other t. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.